Treatment of aggressive non-Hodgkin's lymphoma in frail patients: cardiac comorbidities and advanced age
The decisive factor in selecting a treatment regimen for a frail patient with aggressive non-Hodgkin’s lymphoma is identifying whether a patient is fit enough to tolerate curative-intent anthracycline-containing regimens or too frail and therefore at risk of being undertreated. As cardiac comorbidities are an important contributor to both the health status and the selection of treatment, cardiovascular profiling and baseline risk stratification prior to treatment should be considered. Comprehensive geriatric assessment is an efficient means of identifying elderly patients with non-Hodgkin’s lymphoma who may benefit from a curative treatment approach. If anthracycline-based therapy is not suitable, alternative treatment options are available in frail patients with cardiac comorbidities, but these must be adjusted to the patient’s health status to achieve a maximal benefit–risk ratio.
|Keywords||cardiac comorbidities • elderly • frail • non-Hodgkin’s lymphoma • treatment|
|Persistent URL||dx.doi.org/10.2217/fon-2019-0019, hdl.handle.net/1765/118232|
Lugtenburg, P.J, Lyon, A.R., Mark, R., & Luminari, S. (2019). Treatment of aggressive non-Hodgkin's lymphoma in frail patients: cardiac comorbidities and advanced age. Future Oncology, 15(11), 1197–1205. doi:10.2217/fon-2019-0019